SQI Diagnostics (TSXV:SQD.H) - Aandelenkoers, Nieuws & Analyse

SQD.H Overzicht aandelen

A precision medicine company, discovers, develops, and commercializes rapid diagnostic testing services for healthcare providers, patients, and consumers worldwide.

Over het bedrijf

SQD.H fundamentele analyse
Sneeuwvlok Score
Waardering	2/6
Toekomstige groei	0/6
Prestaties in het verleden	0/6
Financiële gezondheid	0/6
Dividenden	0/6

Beloningen

Risicoanalyse

Does not have a meaningful market cap (CA$6M)

Negative shareholders equity

Shares are highly illiquid

Latest financial reports are more than a year old

+ 2 meer risico's

SQI Diagnostics Inc. Concurrenten

Scryb

CNSX:SCYB

CA$4.4m

ASEP Medical Holdings

CNSX:ASEP

CA$5.4m

Frequency Exchange

TSXV:FREQ

CA$7.1m

Evome Medical Technologies

TSXV:EVMT

CA$9.9m

Prijsgeschiedenis en prestaties

Overzicht van alle hoogtepunten, veranderingen en prijsdalingen voor SQI Diagnostics
Historische aandelenkoersen
Huidige aandelenkoers	CA$0.015
52 Week Hoogtepunt	CA$0.02
52 Week Laag	CA$0.015
Bèta	-0.38
11 maand verandering	n/a
3 maanden verandering	n/a
1 Jaar Verandering	n/a
33 jaar verandering	-90.91%
5 jaar verandering	-88.00%
Verandering sinds IPO	-99.23%

Recent nieuws en updates

Recent updates

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Dec 22

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Nov 17

Rendement voor aandeelhouders

	SQD.H	CA Medical Equipment	CA Markt
7D	0%	-3.0%	-1.5%
1Y	n/a	-7.7%	21.1%

Rendement versus industrie: Insufficient data to determine how SQD.H performed against the Canadian Medical Equipment industry.

Rendement versus markt: Insufficient data to determine how SQD.H performed against the Canadian Market.

Prijsvolatiliteit

Is SQD.H's price volatile compared to industry and market?
SQD.H volatility
SQD.H Average Weekly Movement	n/a
Medical Equipment Industry Average Movement	13.4%
Market Average Movement	8.3%
10% most volatile stocks in CA Market	17.5%
10% least volatile stocks in CA Market	2.9%

Stabiele aandelenkoers: SQD.H has not had significant price volatility in the past 3 months.

Volatiliteit in de loop van de tijd: Insufficient data to determine SQD.H's volatility change over the past year.

Over het bedrijf

Opgericht	Werknemers	CEO	Website
1999	n/a	Andrew Morris	www.sqidiagnostics.com

SQI Diagnostics Inc. Samenvatting

Hoe verhouden de winst en inkomsten van SQI Diagnostics zich tot de beurswaarde?
SQD.H fundamentele statistieken
Marktkapitalisatie	CA$6.11m
Inkomsten(TTM)	-CA$19.14m
Inkomsten(TTM)	CA$3.05m

2.0x

P/S-verhouding

-0.3x

Koers/Winstverhouding

Is SQD.H overgewaardeerd?

Zie Reële waarde en waarderingsanalyse

Inkomsten en omzet

Belangrijkste winstgevendheidsstatistieken uit het laatste winstverslag (TTM)
SQD.H resultatenrekening (TTM)
Inkomsten	CA$3.05m
Kosten van inkomsten	CA$3.19m
Brutowinst	-CA$140.00k
Overige uitgaven	CA$19.00m
Inkomsten	-CA$19.14m

Laatst gerapporteerde inkomsten

Mar 31, 2023

Volgende inkomensdatum

n.v.t.

Winst per aandeel (EPS)	-0.047
Brutomarge	-4.60%
Nettowinstmarge	-628.51%
Schuld/Eigen Vermogen Verhouding	-103.3%

Hoe presteerde SQD.H op de lange termijn?

Bekijk historische prestaties en vergelijking

SQD.H Overzicht aandelen

Beloningen

Risicoanalyse

SQI Diagnostics Inc. Concurrenten

CNSX:SCYB

CA$4.4m

CNSX:ASEP

CA$5.4m

TSXV:FREQ

CA$7.1m

TSXV:EVMT

CA$9.9m

Prijsgeschiedenis en prestaties

Recent nieuws en updates

SQI Diagnostics Inc. Ordinary Shares to Be Deleted from OTC Equity

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Recent updates

SQI Diagnostics Inc. Ordinary Shares to Be Deleted from OTC Equity

SQI Diagnostics Inc. Listing to Transfer to NEX Effective Feb. 20

Clive J. Beddoe Announces Resignation as Director of SQI Diagnostics Inc

SQI Diagnostics Expects its Common Shares to Continue to be Halted from Trading on Exchange and Ultimately Suspended and Delisted Following Completion of the Filing

SQI Diagnostics Inc. Announces Executive Changes

SQI Diagnostics Inc., Annual General Meeting, Jun 30, 2023

Second quarter 2023 earnings released: CA$0.009 loss per share (vs CA$0.007 loss in 2Q 2022)

Insufficient new directors

First quarter 2023 earnings released: CA$0.008 loss per share (vs CA$0.009 loss in 1Q 2022)

SQI Diagnostics Inc., Annual General Meeting, Apr 05, 2023

Full year 2022 earnings released: CA$0.048 loss per share (vs CA$0.031 loss in FY 2021)

SQI Installs Two Rali-Dx Systems in Toronto Hospitals to Fight the Growing Respiratory Health Crisis in Emergency Departments

SQI Diagnostics Inc. announced that it expects to receive CAD 1 million in funding

SQI Diagnostics Inc. announced that it expects to receive CAD 2 million in funding from Federal Economic Development Agency for Southern Ontario

SQI Diagnostics Announces Health Canada Approval of RALI-Dx Severity Triage Test

Third quarter 2022 earnings released: CA$0.012 loss per share (vs CA$0.002 loss in 3Q 2021)

Second quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics (CVE:SQD) Has Debt But No Earnings; Should You Worry?

New York State Approves SQI Diagnostics' Exact Covid-19 Antibody Assay

First quarter 2022 earnings: EPS in line with analyst expectations despite revenue beat

Full year 2021 earnings: EPS in line with analyst expectations despite revenue beat

SQI Diagnostics Systems Inc. signed a definitive agreement to acquire all of the assets underlying Precision Biomonitoring Inc businesses from Precision Biomonitoring Inc. for CAD 6.825 million

SQI Diagnostics Inc. announced that it expects to receive CAD 6 million in funding

Third quarter 2021 earnings released: CA$0.002 loss per share (vs CA$0.005 loss in 3Q 2020)

Is SQI Diagnostics (CVE:SQD) Weighed On By Its Debt Load?

FDA Stops Emergency Use Authorization Review of SQI Diagnostics Inc. RALI-Dx IL-6 Severity Triage Test for Covid-19 Patients

CEO & Director Robert Chioini has left the company

Second quarter 2021 earnings released: CA$0.011 loss per share (vs CA$0.009 loss in 2Q 2020)

Health Check: How Prudently Does SQI Diagnostics (CVE:SQD) Use Debt?

Independent Director recently sold CA$56k worth of stock

Are Insiders Buying SQI Diagnostics Inc. (CVE:SQD) Stock?

First quarter 2021 earnings released: CA$0.012 loss per share (vs CA$0.009 loss in 1Q 2020)

Director exercised options to buy CA$705k worth of stock.

Director recently bought CA$660k worth of stock

New 90-day high: CA$0.40

SQI Diagnostics Inc., Annual General Meeting, Mar 31, 2021

Full year 2020 earnings released: CA$0.032 loss per share (vs CA$0.045 loss in FY 2019)

Is SQI Diagnostics Inc. (CVE:SQD) Popular Amongst Insiders?

SQI Diagnostics Announces Patient Enrollment Begins for its COVID-19 HOME Antibody Test Clinical Study

New 90-day high: CA$0.28

Independent Director exercised options to buy CA$1.7m worth of stock.

If You Had Bought SQI Diagnostics (CVE:SQD) Stock A Year Ago, You Could Pocket A 246% Gain Today

Is SQI Diagnostics (CVE:SQD) Using Debt Sensibly?

Sqi Diagnostics Inc. Updates Clinical Progress on Novel Covid-19 Tests Under Development for U.S. Fda Regulatory Submission

Third quarter earnings released

SQI Diagnostics Inc. Announces Executive Changes

New 90-day high - CA$0.21

Rendement voor aandeelhouders

Prijsvolatiliteit

Over het bedrijf

SQI Diagnostics Inc. Samenvatting

2.0x

-0.3x

Inkomsten en omzet